Mechanistic first-in-human dosability screen for tumor-targeted bispecific antibodies — go/no-go and dosability-margin ranking computed from binding parameters, before any dose exists.
pharmacometricsdrug-developmentimmuno-oncologyfirst-in-human-clinical-trialmabelquantitative-pharmacologypkpd-modellingternary-complexbispecific-antibodydose-selection
-
Updated
Jul 2, 2026 - Python